China’s acceptance, along with India, into the new WHO International Clinical Trials Registry Platform will help spur greater transparency and registration of research involving human’s in the world’s most populous country. But much work is needed to bring China’s trial standards up to standard.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636409 | PMC |
http://dx.doi.org/10.2471/blt.07.010907 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!